Archive - Cancer Currents Blog
- Mouse Study Links Immune Cells to Diarrhea Caused by Chemotherapy
A study in mice sheds light onto how some chemotherapies cause diarrhea. The findings could be the basis for developing new treatments for patients with cancer who develop gastrointestinal side effects from chemotherapy.
- The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr. Judith Paice
Dr. Judith Paice, of the Cancer Pain Program at Northwestern University’s Feinberg School of Medicine, discusses the impacts of the opioid epidemic on cancer patients and how providers can address concerns about opioid misuse when managing cancer pain.
- Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children
The drug sodium thiosulfate can protect the hearing of children with cancer undergoing treatment with the chemotherapy drug cisplatin, results from a new clinical trial show. The trial involved children with a form of liver cancer called hepatoblastoma.
- Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents
Health care providers should emphasize cancer prevention when discussing HPV vaccination with the parents of preteens who are due to receive the vaccine, results from a new study show.
- Can Age Affect Response to Immune Checkpoint Inhibitors?
A new study has linked age with how well patients with melanoma responded to treatment with immune checkpoint inhibitors. Experiments in mice suggested that the response pattern may be due to an age-related shift in the kinds of immune cells in tumors.
- Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research Stalwart, Dies
Many in the cancer research and NIH community are mourning the loss of long-time NCI senior leader Alan Rabson, M.D., who passed away on July 4, at the age of 92. His career spanned 6 decades, including research on tumor virology and cancer pathology and senior NCI leadership roles.
- NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials
The NCI Experimental Therapeutics (NExT) program works with researchers and top scientific experts to advance promising or novel cancer therapies from the earliest stages of research to human clinical trials.
- Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer
Results from two clinical trials are expected to improve the outlook for some people with early-stage pancreatic cancer. Altering the chemotherapy drugs used and the timing of treatment substantially improved survival.
- Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia
FDA expanded the approval of venetoclax (Venclexta) for people with chronic lymphocytic leukemia (CLL) to include those whose cancer has progressed after previous treatment, regardless of whether their cancer cells have the deletion 17p gene alteration.
- Do Frequent Follow-Up Tests Benefit Colorectal Cancer Survivors?
Two studies examined the impact of more frequent follow-up testing for cancer recurrence in colorectal cancer survivors. Learn whether the studies showed that frequent testing improved survival.
- Biosimilars for Cancer Emerge as Patents on Widely Used Biological Drugs Expire
As the patents on some widely used drugs to treat cancer expire in the coming years, biosimilar drugs are being developed for the treatment of patients with cancer. Are biosimilars effective and will they expand treatment options for patients?
- Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia
This NCI-funded Children’s Oncology Group trial tested the addition of nelarabine (Arranon) to standard treatment for children and young adults with T-cell acute lymphoblastic leukemia (T-ALL).
- OncoArray Links Dozens of DNA Variants to Risk for Common Cancers
Researchers with the NCI-supported GAME-ON initiative and OncoArray Network are publishing studies identifying dozens of new genetic variants associated with the risk for developing some of the most common cancers.
- Maximizing the Prospects for Progress Against Cancer
NCI Director Dr. Norman Sharpless highlights some of the important research findings from the 2018 American Society of Clinical Oncology annual meeting and discusses the rapid pace of progress in cancer research.
- Selumetinib Continues to Show Promise in Children with NF1
In a phase 2 clinical trial, the investigational drug selumetinib shrank tumors in some children with the genetic syndrome neurofibromatosis type 1 (NF1). The tumors, called neurofibromas, can cause pain, difficulty breathing or walking, and disfigurement.
- Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia
People diagnosed with hairy cell leukemia (HCL) may have an effective new treatment option, a type of drug called an immunotoxin. Read more about how this treatment, moxetumomab pasudotox, fared in a phase 3 clinical trial in patients with advanced HCL.
- Easing Concerns about Giving Research Study Participants Their Genetic Test Results
Do cancer study participants want to receive their genetic test results? A recent study involving women with a history of breast cancer tested an approach for returning genetic research results and evaluated the impact those results had on the women.
- New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers
Flushing the bladder with the chemotherapy drug gemcitabine after tumors have been removed surgically may reduce the risk of low-grade bladder cancer returning, according to the results of a large clinical trial.
- Experimental Cancer Drug Metarrestin Targets Metastatic Tumors
Researchers have struggled to develop therapies to treat tumors that have spread to other parts of the body. In a new study, researchers tested whether the experimental drug metarrestin can selectively shrink metastases in mouse models of aggressive pancreatic cancer.